Oculis Holding AG (NASDAQ:OCS - Get Free Report) traded down 0.2% on Monday . The stock traded as low as $22.55 and last traded at $22.86. Approximately 73,336 shares changed hands during mid-day trading, a decline of 42% from the average session volume of 126,316 shares. The stock had previously closed at $22.91.
Analyst Upgrades and Downgrades
Several equities analysts have recently issued reports on the company. Chardan Capital restated a "buy" rating and set a $28.00 target price on shares of Oculis in a research report on Tuesday, January 7th. HC Wainwright restated a "buy" rating and set a $30.00 price objective on shares of Oculis in a report on Monday, January 6th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $28.80.
View Our Latest Research Report on OCS
Oculis Trading Up 0.2 %
The company has a market capitalization of $897.08 million, a price-to-earnings ratio of -11.48 and a beta of -0.25. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.02 and a quick ratio of 4.02. The business's 50-day moving average price is $19.10 and its two-hundred day moving average price is $15.40.
Institutional Trading of Oculis
An institutional investor recently raised its position in Oculis stock. abrdn plc boosted its position in Oculis Holding AG (NASDAQ:OCS - Free Report) by 23.0% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 1,009,424 shares of the company's stock after acquiring an additional 188,871 shares during the period. abrdn plc owned 2.49% of Oculis worth $17,150,000 as of its most recent SEC filing. 22.30% of the stock is owned by institutional investors and hedge funds.
About Oculis
(
Get Free Report)
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.
Read More
Before you consider Oculis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oculis wasn't on the list.
While Oculis currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
